



FANC

FEDERAAL AGENTSCHAP VOOR
NUCLEAIRE CONTROLE



AFCN

AGENCE FÉDÉRALE DE
CONTRÔLE NUCLÉAIRE

Regulatory challenges in the monitoring of medical radioactive effluents

ALLIANCE Webinar 2nd June 2022

Geert Biermans
geert.biermans@fanc.fgov.be

International and National Framework

- **EURATOM 35/36 + Recommendations**



- **Oslo-Paris Convention (OSPAR)**

- Protection of North Sea and N Atlantic
- Reporting liquid releases and monitoring of coastal waters
- Nuclear, Medical and NORM



- **FANC Law and Royal Decree on Radiation Protection**

- Monitoring of natural and artificial nuclides in the environment
- Licensing of practices
- Radiological Impact



Radioactivity Monitoring in Belgium


- **Source monitoring:**

- Licensing
- Inspections and Measurements
- Independent verification

→ For medical facilities, limited because of calculations or decay storage.

- Environmental monitoring through **sampling**
- **Early Warning Network (TELERAD)**

→ Focus on releases from NPP and NORM



Challenges

- **Increase in the amount of facilities**
 - Does this impact our approach?
 - Does this increase the overall environmental impact?
- **Increase in the amount of different therapies**
 - 'exotic' radionuclides with unknown environmental behaviour
 - How do you factor this into an evaluation of novel and promising therapies?
- **Change in patient treatment practices**
 - risk of mismatch between impact study and practice
- **Increased international focus (EC, OSPAR, ...)**


→ Not a new issue. So our colleague Jurgen Claes set up a measurement campaign in 2012/3 as a pilot study to underpin our OSPAR data .

Measurement Campaign 2012/3

- **Objectives**
 - Study the **behaviour** of medical liquid discharges
 - Study the impact on workers in **Wastewater Treatment Plants (WTP)**
- **How?**
 - Immersed **gammасpectrometry** probes in inlet and outlet of WTP
 - **Lab** measurements (sludge and water)
 - Ambient dose rate in WTP
- **Where?**
 - WTP downstream of 5 major medical facilities





Results at WTP inlet





Results at WTP inlet

Facility 1



Facility 2




Results at WTP Inlet

- **What did we find?**
 - **Tc-99m** detected frequently: < 300 Bq/l, max 1100 Bq/l
 - **I-131** detected regularly: < 45 Bq/l, max 4800 Bq/l
 - **I-123**, **Sm-153**, **Ir-192** and **F-18** detected occasionally
- In general, **concentrations in compliance** with GRPIR-2001, with exception of I-131 (**exceeds limit of 45 Bq/l** in several installations)
- **Several explanations possible**, but difficult to trace back
 - **several sites** on the same sewer (R&D, Hospital,...)
 - but: can be used as a **screening tool** for inspection campaign

Ambient Dose rate in WTP facilities


- Gamma probe was located outside, so less or **no shielding of metal and concrete**
- Ambient **dose rate peaks observed**
- Peaks are due to (high concentration of) **I-131**; no influence of Tc-99m on ambient dose rate
- Radionuclides with **higher energy gamma rays** can increase temporarily ambient dose rate
 - **I-131**: 95% gamma in range of 280 to 640 keV
 - **Tc-99m**: 89% gamma of 140 keV
- **No long term increase** in ambient dose rate in WTP → **limited impact**.



WTP Sludge and outlet

- Medical radionuclides are **present in sludge**
- In general, more **I-131** in dried sludge (fixation)
- For **Tc-99m**, concentration sometimes higher in fresh, sometimes higher in dried sludge:
- Radionuclides tend to **concentrate in dried sludge**
- **Higher transit time** for dried sludge (independent of WTP processes, weather influence/amount of rain,...)
- Short half-life can **offset the concentration effect** (Tc-99m ~ 6 hours)
- **Concentrations in compliance** with GRPIR-2001 (for solids)
- **No increase in ambient dose rate**
- **No radioactivity measured at the WTP outlet** (apart from Tc99m at one plant < 10 Bq/L)

WTP	Fresh Sludge (Bq/kg)		Dry Sludge (Bq/kg)	
	Tc-99m	I-131	Tc-99m	I-131
Facility 1	< DL to 22	< DL to 22	< DL	170
Facility 2	5 to 150	< DL to traces	< DL	5
Facility 3	<DL to 2	5 to 10	< DL	22
Facility 4	<DL to 21	10 to 22	70	50
Facility 5	11	6	55	20



Conclusions and Regulatory priorities

- Impact of medical releases **limited**
- We do measure radionuclides, sometimes in high concentrations, but only upstream from WTP
- **Tracing releases back to origin** not always straightforward
- What is the impact of **novel treatments**, and **novel or evolving practices**?
- **Modelling** of release + WTP system is of prime interest → *see presentation Jordi*
- ‘incident’ scenario’s

